Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 9 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 9 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

9Total
Not Applicable (5)
P 1 (4)

Trial Status

Completed9

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 9 completed trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07763899Not ApplicableCompletedPrimary

Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study.

NCT07763964Not ApplicableCompletedPrimary

Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.

NCT07763951Not ApplicableCompletedPrimary

Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.

NCT07698275Not ApplicableCompletedPrimary

Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted Conditions

NCT07624357Phase 1CompletedPrimary

Bioequivalence Study of Vortioxetine in 20 mg Coated Tablets in Healthy Subjects Under Fasting Conditions

NCT07495007Phase 1CompletedPrimary

An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection

NCT07479108Not ApplicableCompletedPrimary

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions

NCT06773767Phase 1Completed

Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state.

NCT04155814Phase 1CompletedPrimary

Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects

Showing all 9 trials

Research Network

Activity Timeline